JNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of ...

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as ...

The GLP-1s include semaglutide (Ozempic, Wegovy) and the combination of GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound).

According to the FDA, 1 each of the unapproved products were sold on the firm’s websites, Amazon shops, and social media ...

Spinach, broccoli and kale are often hailed as healthy foods because they’re filled with nutrients while being low in ...

The rise in Biocon stock was also fuelled after Jefferies upgraded the stock to 'Buy', and raised the target to Rs 400 ...

Local citizens living with arthritis may find relief through DeTar Healthcare System's upcoming 2025 Arthritis Seminar Series ...

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Rheumatoid Arthritis.

University of Birmingham researchers have been awarded £3.5 million funding from Johnson & Johnson to investigate mechanisms of response and non-response to biologic and targeted synthetic therapies ...

Etanercept biosimilar is under clinical development by Mabxience Holding and currently in Phase III for Rheumatoid Arthritis.